Mitozantrone-induced onycholysis. A series of five cases.
The anthracenedione cytotoxic agent, mitozantrone, has a well-established place in the treatment of acute leukaemia, lymphoma, breast carcinoma and other malignant tumours. In general it is well tolerated apart from myelosuppression and dose-related cardiotoxicity. Alopecia is a common side-effect with mitozantrone but otherwise the skin and its appendages are rarely affected. We present five cases of mitozantrone-induced onycholysis.
Creamer
J D
JD
Department of Dermatology, St. George's Hospital, London, UK.
Mortimer
P S
PS
Powles
T J
TJ
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy; D005260:Female; D005534:Foot Diseases / Q000139:chemically induced*; D006801:Humans; D008875:Middle Aged; D008942:Mitoxantrone / Q000009:adverse effects* / Q000627:therapeutic use; D009260:Nail Diseases / Q000139:chemically induced*
D000970:Antineoplastic Agents; D008942:Mitoxantrone